Looking for passive income after the RBA's rate cut? Here are ten high-conviction ASX dividend shares to consider today.

Foreign buyers in the ASX has dwindled over time, as valuations have made the Australian equities market the second-most ...

The ASX is often criticised for underrepresenting the technology sector. However, this ASX 200 stock has outperformed Nvidia ...

This week’s Bulls N’ Bears ASX Runner of the Week is… Oceana Lithium, after a capital raise to fill its coffers ahead of base ...

The Australian market has shown resilience, with the ASX 200 closing up 0.52% at 8,386 points, driven by strong performances in the Energy and Health Care sectors. While penny stocks might seem like a ...

As Nanosonics scores FDA De Novo win, investors are now watching EMVision’s brain scanner in its US trials with Mayo Clinic.

ASX stocks wobble, Bitcoin soars and Mayne gets smashed – a messy day so far that has investors reassessing risk and red ...

Cautious investors helped drive the Australian sharemarket higher on the back of a retreat in US treasury yields and low ...

Good morning everyone and welcome to Rise and Shine on Thursday, May 22, 2025. Here’s what you should know before the ASX ...

When it comes to building long-term wealth, few strategies are as effective — or as simple — as buying high-quality ASX ...

Vitrafy Life Sciences' estimated fair value is AU$1.37 based on 2 Stage Free Cash Flow to Equity. Vitrafy Life Sciences' AU$1.50 share price indicates it is trading ...